期刊文献+

他汀类药物致急性冠脉综合征患者肝功能异常情况观察 被引量:11

下载PDF
导出
摘要 目的观察他汀类药物致急性冠脉综合征(ACS)患者肝功能异常的情况。方法回顾性分析370例服用他汀类药物ACS患者的临床资料,ALT升高>3倍正常上限判断为肝功能异常。结果肝功能异常33例(8.9%),服药后(6.1±1.4)d出现,均无症状;肝功能异常者男性比例(93.9%)高于肝功能无异常者(67.4%),P<0.01;相关分析显示,肝功能异常与年龄、吸烟、饮酒、脂肪肝、CK、CK-MB、Cr、BNP均无明显相关(P均<0.05)。肝功能异常者他汀药物停用8例、减量5例、改普伐他汀14例、继续应用6例,均加用水飞蓟素,肝功能指标下降。结论 ACS患者服用他汀后无症状性肝功能异常发生率较高,男性患者多见;调整治疗方案后肝酶可明显下降。
出处 《山东医药》 CAS 北大核心 2015年第24期56-57,共2页 Shandong Medical Journal
  • 相关文献

参考文献15

  • 1Sandra Lewis.Lipid-lowering therapy: who can benefit[J]. Vascular Health and Risk Management . 2011 (defa)
  • 2Vasilios G Athyros,Konstantinos Tziomalos,Thomas D Gossios,Theodora Griva,Panagiotis Anagnostis,Konstantinos Kargiotis,Efstathios D Pagourelias,Eleni Theocharidou,Asterios Karagiannis,Dimitri P Mikhailidis.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis[J]. The Lancet . 2010 (9756)
  • 3Rossana M. Calderon,Luigi X. Cubeddu,Ronald B. Goldberg,Eugene R. Schiff.Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma[J]. Mayo Clinic Proceedings . 2010 (4)
  • 4Tomotaka Dohi,Katsumi Miyauchi,Shinya Okazaki,Takayuki Yokoyama,Naotake Yanagisawa,Hiroshi Tamura,Takahiko Kojima,Ken Yokoyama,Takeshi Kurata,Hiroyuki Daida.Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow-up study[J]. Atherosclerosis . 2009 (2)
  • 5Edward J. Mills,Beth Rachlis,Ping Wu,Philip J. Devereaux,Paul Arora,Dan Perri.Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments[J]. Journal of the American College of Cardiology . 2008 (22)
  • 6Scott M. Grundy,James I. Cleeman,C. Noel Bairey Merz,H. Bryan Brewer,Luther T. Clark,Donald B. Hunninghake,Richard C. Pasternak,Sidney C. Smith,Neil J. Stone.Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines[J]. Circulation: Journal of the American Heart Association . 2004 (2)
  • 7Terry A. Jacobson.Comparative pharmacokinetic interaction profiles of pravastatin , simvastatin , and atorvastatin when coadministered with cytochromeP450 inhibitors[J]. The American Journal of Cardiology . 2004 (9)
  • 8Marc A. Pfeffer,Anthony Keech,Frank M. Sacks,Stuart M. Cobbe,Andrew Tonkin,Robert P. Byington,Barry R. Davis,Carola P. Friedman,Eugene Braunwald.Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project[J]. Circulation: Journal of the American Heart Association . 2002 (20)
  • 9DE Cohen,FA Anania,N Chalasani,National Lipid Association Statin Safety Task Force Liver Expert Panel.An assessment of statin safety by hepatologists. The American Journal of Cardiology . 2006
  • 10Koren Michael J,Feldman Theodore,Mendes Robert A.Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years. Clinical Cardiology . 2009

二级参考文献1

共引文献7

同被引文献96

引证文献11

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部